Maximum Recommended Daily Dose of Testosterone for Postmenopausal Women
The maximum recommended daily dose of testosterone supplementation for postmenopausal women is 300 mcg (0.3 mg) per day via transdermal patch or gel, with the goal of maintaining testosterone concentrations within the physiological premenopausal female range. 1
Dosing Framework Based on Guidelines
The 2019 Global Consensus Position Statement provides the most authoritative guidance on testosterone dosing for postmenopausal women 1:
Key Dosing Principles
- Target physiological concentrations: All testosterone therapy should aim to approximate premenopausal testosterone levels, not exceed them 1
- Avoid supraphysiological doses: Preparations that result in supraphysiological concentrations (including pellets and high-dose injections) are explicitly not recommended 1
- Route matters: Oral testosterone is not recommended due to adverse lipid effects; transdermal (patches, gels, creams) is the preferred route 1
Specific Dose Ranges from Research
The evidence demonstrates that:
- 300 mcg/day transdermal patch was the highest effective dose studied in major trials, showing modest but meaningful improvement in sexual function (approximately one additional satisfying sexual event per month) 2
- 150 mcg/day showed less consistent benefit 2
- Testosterone gel at 4.4 mg/day raised testosterone to mid-to-high normal premenopausal range in pharmacokinetic studies 3
- Higher gel doses (8.8-13.2 mg/day) raised testosterone above physiological range and are therefore not appropriate 3
Monitoring Requirements
Critical safety parameters 1:
- Measure baseline total testosterone before starting
- Recheck testosterone at 3-6 weeks after initiation
- Monitor every 6 months thereafter with clinical assessment for androgen excess
- Discontinue if no benefit by 6 months
Target testosterone range: Maintain levels within the premenopausal female physiological range (specific cutoffs vary by assay, but generally total testosterone should remain below 70-80 ng/dL) 1
Important Caveats
The only evidence-based indication for testosterone in women is treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women after formal biopsychosocial assessment 1. There is insufficient evidence to recommend testosterone for:
- Bone health
- Muscle strength
- Cognitive function
- Energy levels
- Women without sexual dysfunction 1
Safety limitations:
- Safety data beyond 24 months are not available 1
- Studies excluded women at high cardiometabolic risk 1
- Mild androgenic side effects (acne, facial/body hair) occur but serious virilization (voice changes, clitoromegaly) does not occur at physiological doses 1
Practical reality: No FDA-approved female testosterone formulation exists in the United States. Off-label use of male formulations at approximately one-tenth the male dose is considered reasonable when hormone concentrations are maintained in the physiological female range 1. Compounded preparations should only be used if approved products are unavailable, and only from pharmacies meeting quality standards 1.
Bottom line: The upper limit is 300 mcg/day transdermal, but this must be individualized based on measured testosterone levels to ensure physiological—not supraphysiological—concentrations are achieved.